{"pub": "yahoo", "url": "https://finance.yahoo.com/news/u-sec-sues-mylan-concealing-141604060.html", "downloaded_at": "2019-09-27 15:07:38.043513+00:00", "title": "Mylan to pay $30 million to settle U.S. SEC charges over EpiPen", "language": "en", "text": "Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux\n\n(Reuters) - Mylan NV <MYL.O> will pay a $30 million civil fine to settle U.S. Securities and Exchange Commission charges it concealed a possible loss related to a federal probe on whether it overcharged Medicaid by hundreds of millions of dollars for sales of its EpiPen Auto-Injector.\n\nThe SEC accused Mylan of misleading investors by failing to disclose or set aside money for the two-year probe by the U.S. Department of Justice before it announced a $465 million settlement in 2016.\n\nAccording to the SEC, Mylan's misclassification of EpiPen, which is used to treat severe allergic reactions, as a \"generic\" drug allowed the company to pay much lower rebates to the government than if it were classified as a \"branded\" drug.\n\nMylan did not admit or deny wrongdoing in agreeing to settle. In a statement, the company called the settlement \"the right course of action.\"\n\n\n\n\n\n(Reporting by Jonathan Stempel in New York; Editing by Susan Fenton and Dan Grebler)", "description": "The SEC accused Mylan of misleading investors by failing to disclose or set aside money for the two-year probe by the U.S. Department of Justice before it announced a $465 million settlement in 2016.  According to the SEC, Mylan's misclassification of EpiPen, which is used to treat severe allergic", "authors": [], "top_image": "https://s.yimg.com/uu/api/res/1.2/D0qD4T19SmmEUPkHizA.ew--~B/aD0zMjA7dz00NDk7c209MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en-US/reuters-finance.com/43691877675c7feb6fd60ef234038554", "published_at": "2019-09-27"}